NCT01893372 - Eltrombopag With or Without Hypomethylating Agent After Hypomethylating Agent Failure For Patients With Myelodysplastic Syndrome (MDS) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

January 6, 2019

Study Completion Date

January 6, 2019

Conditions

Leukemia

Interventions

DRUG

Eltrombopag

200 mg by mouth daily in a 28 day cycle.

DRUG

Hypomethylating Agent (HMA)

The choice of HMA agent (e.g. azacitidine or decitabine) will be the HMA the patient has received prior to enrollment on study.

Trial Locations (1)

University of Texas MD Anderson Cancer Center, Houston